Peripheral Arterial Disease Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The peripheral arterial disease market size has grown strongly in recent years. It will grow from $4.36 billion in 2024 to $4.76 billion in 2025 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period can be attributed to innovative medical devices, gene therapy and regenerative medicine, pharmacogenomics, digital health and remote monitoring.

The peripheral arterial disease market size is expected to see strong growth in the next few years. It will grow to $6.62 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to interdisciplinary care teams, minimally invasive interventions, lifestyle and exercise prescriptions. Major trends in the forecast period include vascular tele-rehabilitation, multimodal pain management, wound care advances, public health campaigns.

The increasing prevalence of cardiac diseases is expected to fuel the growth of the peripheral arterial disease market in the coming years. Cardiac disease refers to heart conditions that affect the major blood vessels supplying blood to the heart muscle. Treatments for peripheral arterial disease help improve blood circulation, reduce cardiovascular risks, alleviate symptoms, and enhance overall quality of life for cardiac patients. For example, in December 2023, reports from The Australian Bureau of Statistics (ABS), an Australian government agency, showed that in 2022, approximately 1.3 million people (5.2% of the population) were affected by heart, stroke, and vascular diseases. Additionally, a report from the American College of Cardiology in April 2022 predicted a 30.7% increase in risk factors for ischemic heart disease, reaching 29 million by 2025. Thus, the growing prevalence of cardiac diseases is driving the expansion of the peripheral arterial disease market.

The increasing prevalence of diabetes is anticipated to accelerate the growth of the peripheral arterial disease market. Diabetes is a chronic metabolic disorder characterized by high blood glucose levels. As diabetes rates rise, so does the demand for treatments related to the condition. Diabetes is also a significant contributor to peripheral arterial disease (PAD), as individuals with diabetes are at an elevated risk of developing atherosclerosis, the most common cause of PAD, which requires medical intervention. For instance, in March 2024, reports from The Office for Health Improvement and Disparities (OHID), a UK government agency, revealed that the percentage of individuals with type 1 diabetes receiving eight key care processes increased by 22% between March 2022 and March 2023, while the increase for type 2 diabetes was 21%. Consequently, the rising prevalence of diabetes is a key factor driving the growth of the peripheral arterial disease market.

Leading companies in the peripheral arterial disease market are focusing on the development of innovative medical devices, such as the intravascular lithotripsy (IVL) catheter, to improve treatment effectiveness, enhance patient outcomes, and reduce recovery times for individuals with vascular conditions. The IVL catheter is a medical device used to treat calcified arterial blockages by delivering controlled shockwaves to break down calcium, which helps restore blood flow and increases vessel flexibility during procedures like angioplasty. For example, in September 2024, Shockwave Medical, Inc., a U.S.-based medical technology firm, introduced the Shockwave E8 peripheral IVL catheter. This device is designed to treat peripheral arterial disease by delivering targeted intravascular lithotripsy, using sonic waves to break down calcium deposits in arterial walls. This innovative technique restores blood flow while minimizing damage to surrounding tissues. The catheter’s advanced design also facilitates easier navigation through complex vascular anatomy, making it suitable for a broader range of patients.

In February 2023, Abbott Laboratories, a prominent US-based pharmaceutical company, successfully completed its acquisition of Cardiovascular Systems Inc. for a total of $890 million. Through this strategic acquisition, Abbott intends to fortify its cardiovascular portfolio by integrating new and complementary technologies. Cardiovascular Systems Inc., based in the US, is a leading medical device company specializing in the development and commercialization of products tailored for the treatment of peripheral and coronary vascular disease.

Major companies operating in the peripheral arterial disease market are Cardinal Health Inc., Johnson and Johnson Limited, Abbott Laboratories, Medtronic PLC, Becton Dickinson and Company, Koninklijke Philips N.V., Boston Scientific Corporation, B. Braun SE, Terumo Corp., Cook Medical LLC, Penumbra Inc., Shockwave Medical Inc., AngioDynamics Inc., Cardiovascular Systems Inc., ACIST Medical Systems Inc., SurModics Inc., Endologix Inc., BioVentrix Inc., QT Vascular Ltd., Avinger Inc., Mercator MedSystems Inc., VentureMed Group Ltd., Eximo Medical Ltd., LimFlow SA, Contego Medical LLC.

North America was the largest region in the peripheral artery disease market in 2024. The regions covered in peripheral artery disease report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the peripheral artery disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The peripheral artery disease market consists of sales of cardiac medical devices and diagnostic tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Peripheral Arterial Disease (PAD) is a medical condition characterized by the narrowing or obstruction of arteries, primarily those supplying blood to the legs and feet. This condition is a type of atherosclerosis, where fat deposits (plaque) accumulate in the arteries, leading to diminished blood flow. The treatment of PAD typically involves a multifaceted approach, incorporating lifestyle adjustments, medication regimens, and medical procedures. The objective is to augment blood supply to the affected extremities, alleviate symptoms, and mitigate associated risks.

The primary treatment modalities for Peripheral Arterial Disease encompass devices, catheters, drugs, and other interventions. Devices for PAD pertain to specialized medical tools employed in the diagnosis, treatment, and management of the condition. These treatments can be administered through various routes, including oral, parenteral, and others. They find application across a spectrum of end-users, such as hospitals, specialty clinics, and other healthcare facilities.

The peripheral artery disease market research report is one of a series of new reports that provides peripheral artery disease market statistics, including peripheral artery disease industry global market size, regional shares, competitors with a peripheral artery disease market share, detailed peripheral artery disease market segments, market trends and opportunities and any further data you may need to thrive in the peripheral artery disease industry. This peripheral artery disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.